Alzheimer’s can take a woman out of the workforce twice. The first time, she leaves to care for a parent or spouse who has the disease. The second time, she develops it herself.
We file those two exits in different places. One is a medical issue, while the other is a family responsibility. We never account for what they cost together, so companies don’t see how much of their workforce they’re losing, or why.
November is both National Alzheimer’s Disease Awareness Month and National Family Caregivers Month. The calendar already connects them. Our budgets need to catch up.
Women Carry Most of the Diagnoses
Almost two-thirds of Americans living with Alzheimer’s are women, according to the Alzheimer’s Association. A woman in her 60s is about twice as likely to develop Alzheimer’s over the rest of her life as she is to develop breast cancer.
I run a breast imaging company, so I understand why breast health needs attention, investment and better diagnostics. I also know how fast women’s health gets waved off, even in rooms that choose to hear about it.
Several years ago, I pitched at an invited angel investor event. About seven minutes in, a gentleman in his 70s unmuted himself and asked, “Is breast cancer really still a thing?” I said yes and kept going. Afterward, I declined to pursue the group’s money. My company was running on fumes, and I still wouldn’t take capital from that room.
If investors can question the most recognized disease in women’s health, imagine how easily brain health gets overlooked. Brain health belongs in the same conversation about prevention, early detection, access to care, and keeping women in the workforce. Women don’t experience their health in the separate categories we use to fund it.
Longer life expectancy explains part of women’s greater Alzheimer’s burden. Researchers are also studying biological, genetic, and social differences. What we don’t know, we don’t know because the capital hasn’t gone to studying it, especially in women.
The question deserves more precision than “women live longer.” It also deserves more discipline than declaring menopause the answer. Research into hormonal transitions and brain health is unsettled. It should guide better questions, not premature promises.
My question for investors is straightforward: when you evaluate an Alzheimer’s diagnostic, do you examine whether it performs differently in women, reaches them early enough, and connects them to care?
A market with this many women deserves more than a demographic note in a pitch deck. It deserves evidence that shapes product development, clinical validation, and access from day one.
The Caregiving Cost Companies Aren’t Counting
Then there’s the other side of the diagnosis. The Alzheimer’s Association’s 2026 Facts and Figures report estimates that nearly 13 million Americans provided unpaid care for people with Alzheimer’s or other dementias in 2025. About two-thirds of those caregivers are women. Together, they provided more than 19 billion hours of care, valued at $446.3 billion.
The U.S. isn’t an outlier. Globally, women perform about three-quarters of all unpaid care work, worth roughly $11 trillion a year, or 9% of global GDP.
Calling that care unpaid describes the payment arrangement. It tells us very little about the cost.
Consider a woman who cuts her hours to supervise a parent with dementia. Her paycheck shrinks immediately. Her retirement contributions may fall, along with employer contributions and years of investment growth. She may turn down a promotion, or stop pursuing one. She may leave the workforce entirely. When the caregiving ends, her earnings and her career trajectory don’t automatically return.
The retirement loss is the line item I’d put in front of a CFO first. The smaller paycheck is visible today. The retirement gap can keep compounding long after the caregiving shift ends.
The company pays, too. These women are often at the peak of their careers, carrying institutional knowledge, running teams, and driving growth. Replacing her costs more than the CFO would like to admit.
The health burden is documented as well. The Alzheimer’s Association reports that 59% of dementia caregivers experience high or very high emotional stress. A care model that depends on women continually absorbing more work also has to account for her sleep, her own medical appointments, and her capacity to stay employed.
These costs are scattered across payroll, recruiting, household finances, and healthcare. A manager sees an absence. HR sees a resignation. A family watches its savings disappear. Companies track turnover and productivity dips, but they rarely ask why women leave. No single decision-maker owns the full picture, so each consequence gets treated as an isolated problem.
We Fund the Diagnostic. Who Funds the Care?
The separation shapes investment too. A diagnostic can have a reimbursement pathway. A daughter coordinating appointments, managing medications, and keeping her mother safe usually has no comparable funding behind her work. We can price the test while leaving the care that follows to whoever is available.
Japan made a different financing choice, and the right one. Since 2000, it has run mandatory long-term care insurance, with contributions starting at age 40. Municipalities administer it, and it’s funded by insurance premiums, public money, and user copayments. It covers care at home and in facilities, with eligibility based on assessed need and tighter rules for people aged 40 to 64.
The lesson is the financing principle: care is a predictable social need that warrants a shared funding structure. The U.S. can adopt that principle without copying every feature of Japan’s system.
Start with One Number
CFOs and HR leaders should start with one number: the estimated annual cost of employees leaving because of caregiving. Build it from existing turnover data and voluntary, confidential employee feedback. State the assumptions. Don’t pretend it captures everything.
Then compare that with the cost of practical support: paid caregiver leave, flexible schedules, care navigation, and respite benefits.
Women’s health is infrastructure. Alzheimer’s exposes what happens when we budget for the disease and assume women will supply the labor around it.
If the business model depends on her working for free, whose return are we actually measuring?